BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 23396354)

  • 1. Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation.
    Horsley AR; Davies JC; Gray RD; Macleod KA; Donovan J; Aziz ZA; Bell NJ; Rainer M; Mt-Isa S; Voase N; Dewar MH; Saunders C; Gibson JS; Parra-Leiton J; Larsen MD; Jeswiet S; Soussi S; Bakar Y; Meister MG; Tyler P; Doherty A; Hansell DM; Ashby D; Hyde SC; Gill DR; Greening AP; Porteous DJ; Innes JA; Boyd AC; Griesenbach U; Cunningham S; Alton EW
    Thorax; 2013 Jun; 68(6):532-9. PubMed ID: 23396354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation.
    Sagel SD; Thompson V; Chmiel JF; Montgomery GS; Nasr SZ; Perkett E; Saavedra MT; Slovis B; Anthony MM; Emmett P; Heltshe SL
    Ann Am Thorac Soc; 2015 May; 12(5):708-17. PubMed ID: 25714657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased Fecal Calprotectin Levels in Cystic Fibrosis Patients After Antibiotic Treatment for Respiratory Exacerbation.
    Schnapp Z; Hartman C; Livnat G; Shteinberg M; Elenberg Y
    J Pediatr Gastroenterol Nutr; 2019 Feb; 68(2):282-284. PubMed ID: 30640865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.
    Lechtzin N; West N; Allgood S; Wilhelm E; Khan U; Mayer-Hamblett N; Aitken ML; Ramsey BW; Boyle MP; Mogayzel PJ; Goss CH
    Contemp Clin Trials; 2013 Nov; 36(2):460-9. PubMed ID: 24055998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.
    Heltshe SL; Goss CH; Thompson V; Sagel SD; Sanders DB; Marshall BC; Flume PA
    Thorax; 2016 Mar; 71(3):223-9. PubMed ID: 25911223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Lung Clearance Index and Magnetic Resonance Imaging for Assessment of Lung Disease in Children with Cystic Fibrosis.
    Stahl M; Wielpütz MO; Graeber SY; Joachim C; Sommerburg O; Kauczor HU; Puderbach M; Eichinger M; Mall MA
    Am J Respir Crit Care Med; 2017 Feb; 195(3):349-359. PubMed ID: 27575911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystic fibrosis: detecting changes in airway inflammation with FDG PET/CT.
    Amin R; Charron M; Grinblat L; Shammas A; Grasemann H; Graniel K; Ciet P; Tiddens H; Ratjen F
    Radiology; 2012 Sep; 264(3):868-75. PubMed ID: 22829680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reasons for heterogeneous change in LCI in children with cystic fibrosis after antibiotic treatment.
    Yammine S; Bigler A; Casaulta C; Singer F; Latzin P
    Thorax; 2014 Feb; 69(2):183. PubMed ID: 23988751
    [No Abstract]   [Full Text] [Related]  

  • 9. Procalcitonin, erythrocyte sedimentation rate and C-reactive protein in acute pulmonary exacerbations of cystic fibrosis.
    Loh G; Ryaboy I; Skabelund A; French A
    Clin Respir J; 2018 Apr; 12(4):1545-1549. PubMed ID: 28884501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A semiquantitative MRI-Score can predict loss of lung function in patients with cystic fibrosis: Preliminary results.
    Schaefer JF; Hector A; Schmidt K; Teufel M; Fleischer S; Graepler-Mainka U; Riethmueller J; Gatidis S; Schaefer S; Nikolaou K; Hartl D; Tsiflikas I
    Eur Radiol; 2018 Jan; 28(1):74-84. PubMed ID: 28664245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional respiratory imaging in relation to classical outcome measures in cystic fibrosis: a cross-sectional study.
    Lauwers E; Snoeckx A; Ides K; Van Hoorenbeeck K; Lanclus M; De Backer W; De Backer J; Verhulst S
    BMC Pulm Med; 2021 Aug; 21(1):256. PubMed ID: 34348676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Author's response: heterogeneity of change in LCI in patients with cystic fibrosis following antibiotic treatment.
    Horsley A
    Thorax; 2014 Feb; 69(2):184. PubMed ID: 24008688
    [No Abstract]   [Full Text] [Related]  

  • 13. Sputum club cell protein concentration is associated with pulmonary exacerbation in cystic fibrosis.
    Laguna TA; Williams CB; Brandy KR; Welchlin-Bradford C; Moen CE; Reilly CS; Wendt CH
    J Cyst Fibros; 2015 May; 14(3):334-40. PubMed ID: 25456770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spirometer-triggered high-resolution computed tomography and pulmonary function measurements during an acute exacerbation in patients with cystic fibrosis.
    Robinson TE; Leung AN; Northway WH; Blankenberg FG; Bloch DA; Oehlert JW; Al-Dabbagh H; Hubli S; Moss RB
    J Pediatr; 2001 Apr; 138(4):553-9. PubMed ID: 11295720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lung clearance index in cystic fibrosis subjects treated for pulmonary exacerbations.
    Sonneveld N; Stanojevic S; Amin R; Aurora P; Davies J; Elborn JS; Horsley A; Latzin P; O'Neill K; Robinson P; Scrase E; Selvadurai H; Subbarao P; Welsh L; Yammine S; Ratjen F
    Eur Respir J; 2015 Oct; 46(4):1055-64. PubMed ID: 26160868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystic fibrosis clinical score: a new scoring system to evaluate acute pulmonary exacerbation.
    Kanga J; Kuhn R; Craigmyle L; Haverstock D; Church D
    Clin Ther; 1999 Aug; 21(8):1343-56. PubMed ID: 10485506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute Pulmonary Exacerbations in Cystic Fibrosis.
    Goss CH
    Semin Respir Crit Care Med; 2019 Dec; 40(6):792-803. PubMed ID: 31659730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity of Lung Clearance Index and chest computed tomography in early CF lung disease.
    Ellemunter H; Fuchs SI; Unsinn KM; Freund MC; Waltner-Romen M; Steinkamp G; Gappa M
    Respir Med; 2010 Dec; 104(12):1834-42. PubMed ID: 20637585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.
    Harris JK; Wagner BD; Zemanick ET; Robertson CE; Stevens MJ; Heltshe SL; Rowe SM; Sagel SD
    Ann Am Thorac Soc; 2020 Feb; 17(2):212-220. PubMed ID: 31604026
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.